August 17, 2023
- August 1, 2023 - A Consortium for Gut-Brain Communication in Parkinson’s Disease (U01 Clinical Trial Not Allowed). See NOFO RFA-DK-22-036.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
The purpose of this Notice is to alert potential applicants to changes in Section III. 3. Additional Information on Eligibility for RFA-DK-22-036 “A Consortium for Gut-Brain Communication in Parkinson’s Disease (U01 Clinical Trial Not Allowed).” This Notice of Funding Opportunity (NOFO) was issued on 8/1/2023. Changes to the NOFO are shown in bold italics below.
Currently, Reads:
Section III. Eligibility Information
3. Additional Information on Eligibility
Number of Applications
The NIH will not accept duplicate or highly overlapping applications under review at the same time, per NIH Grants Policy Statement Section 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:
- A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
- A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
- An application that has substantial overlap with another application pending appeal of initial peer review (see NIH Grants Policy Statement 2.3.9.4 Similar, Essentially Identical, or Identical Applications).
Only one application per institution (normally identified by having a unique UEI or NIH IPF number) is allowed.
Modified to Read (shown in bold italics):
Section III. Eligibility Information
3. Additional Information on Eligibility
Number of Applications
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
The NIH will not accept duplicate or highly overlapping applications under review at the same time, per NIH Grants Policy Statement Section 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:
- A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
- A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
- An application that has substantial overlap with another application pending appeal of initial peer review (see NIH Grants Policy Statement 2.3.9.4 Similar, Essentially Identical, or Identical Applications).
All other aspects of this NOFO remain the same.
Terez Shea-Donohue, Ph.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301 825-2314
Email: terez.shea-donohue@nih.gov
and Human Services (HHS)
